We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Lancet Oncol 2022 Dec 05;[EPub Ahead of Print], SRD Johnston, M Toi, J O'Shaughnessy, P Rastogi, M Campone, P Neven, CS Huang, J Huober, GG Jaliffe, I Cicin, SM Tolaney, MP Goetz, HS Rugo, E Senkus, L Testa, L Del Mastro, C Shimizu, R Wei, A Shahir, M Munoz, B San Antonio, V André, N Harbeck, M Martin